PMID- 18332682
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20211020
IS  - 0955-8810 (Print)
IS  - 0955-8810 (Linking)
VI  - 19
IP  - 2
DP  - 2008 Mar
TI  - Influence of thyroid hormones on 3,4-methylenedioxymethamphetamine-induced 
      thermogenesis and reinforcing strength in monkeys.
PG  - 167-70
LID - 10.1097/FBP.0b013e3282f62c40 [doi]
AB  - In monkeys, elevating ambient temperature has been shown to increase sensitivity 
      to 3,4-methylenedioxymethamphetamine (MDMA) reinforcement. Earlier rodent studies 
      have shown that elevations in thyroid levels (hyperthyroidism) parallel changes 
      in elevating the ambient temperature on MDMA-induced thermogenesis, but the 
      interaction has not been examined in monkeys. This study was designed to evaluate 
      the effects of chronic levothyroxine (3.0 or 4.5 microg/kg/day, intramuscularly; 
      Levo) treatment on MDMA-induced increases in body temperature following 1.5 mg/kg 
      (intravenously) MDMA and self-administration when MDMA (0.03-0.3 mg/kg/injection) 
      and food were available under a concurrent fixed-ratio 30 schedule of 
      reinforcement in rhesus monkeys (n=4). Earlier studies had shown that 1.5 mg/kg 
      MDMA did not affect thermoregulation at 24 degrees C. Chronic Levo treatment 
      resulted in significant increases in MDMA-induced thermogenesis. In the 
      self-administration experiment, MDMA choice increased with dose, such that food 
      was preferred over saline and a low MDMA dose (0.03 mg/kg/injection), whereas 0.1 
      and 0.3 mg/kg/injection MDMA was preferred over food. Although elevating ambient 
      temperature had been shown to increase MDMA potency, there was no effect of 
      chronic Levo treatment on MDMA choice. These results suggest that changes in 
      thyroxine levels do not parallel the changes in ambient temperature in altering 
      the reinforcing strength of MDMA.
FAU - Banks, Matthew L
AU  - Banks ML
AD  - Department of Physiology and Pharmacology, Wake Forest University School of 
      Medicine, Winston-Salem, North Carolina 27157-1083, USA.
FAU - Czoty, Paul W
AU  - Czoty PW
FAU - Sprague, Jon E
AU  - Sprague JE
FAU - Nader, Michael A
AU  - Nader MA
LA  - eng
GR  - DA-06634/DA/NIDA NIH HHS/United States
GR  - F31 DA020281/DA/NIDA NIH HHS/United States
GR  - P50 DA006634-140009/DA/NIDA NIH HHS/United States
GR  - P50 DA006634-160009/DA/NIDA NIH HHS/United States
GR  - P50 DA006634-150009/DA/NIDA NIH HHS/United States
GR  - DA-020281/DA/NIDA NIH HHS/United States
GR  - F31 DA020281-02/DA/NIDA NIH HHS/United States
GR  - P50 DA006634/DA/NIDA NIH HHS/United States
GR  - F31 DA020281-01/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - Animals
MH  - Appetitive Behavior/drug effects
MH  - Choice Behavior/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Hallucinogens/*pharmacology
MH  - Injections, Intramuscular
MH  - Macaca mulatta
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - *Reinforcement Schedule
MH  - Self Administration
MH  - Thermogenesis/*drug effects
MH  - Thyroxine/blood/*pharmacology
PMC - PMC2377416
MID - NIHMS46225
EDAT- 2008/03/12 09:00
MHDA- 2008/06/18 09:00
PMCR- 2009/03/01
CRDT- 2008/03/12 09:00
PHST- 2008/03/12 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/03/12 09:00 [entrez]
PHST- 2009/03/01 00:00 [pmc-release]
AID - 00008877-200803000-00009 [pii]
AID - 10.1097/FBP.0b013e3282f62c40 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2008 Mar;19(2):167-70. doi: 10.1097/FBP.0b013e3282f62c40.